Dialysis world news


Calhoun's Harbin Clinic open and accepting new patients - Calhoun Times

Comprehensive primary and specialty care is right around the corner at the new Harbin Clinic located at 855 Curtis Parkway.

The family medicine practice office of Dr. Ken Howard, Dr. Thomas Self and nurse practitioner Roxanne Phillips has always been an integral part of Gordon County, according to a statement from the clinic.

Dr. Self said so far, he’s seen an average number of patients and it seems to be growing.

“I’ve seen probably about 300 patients,” said Self, who specializes is family medicine.

Self said he’s very happy with the new facility.

“It should be easy to find and we’ll take good care of them,” he said of patients.

Patricia Edward is the medical assistant to Dr. Self. Patient interaction is what she said she enjoys the most.

“I decided to come into this field because I like taking care of people,” Edward said. She’s been with Harbin for seven years.

Physicians care for individuals ages 2 and up while striving to meet the needs of their patients. Dr. Howard and Dr. Self treat and diagnose acute to chronic illness, provide health screenings and counsel patients on lifestyle changes to help prevent illnesses before they develop.

Monthly diabetic education classes to help patients stay informed are also offered.

Dr. Ken Howard started with Harbin in 1996. He said high blood pressure, diabetes, and obesity are some of the main things they see at the clinic.

Although the location has changed Howard said the level of care given to patients hasn’t.

“We have an excellent staff,” Howard said. “We’re going to give the same quality care that we’ve been doing forever,” he added. 

“We want to maintain a good, long-lasting relationship with our patients,” said Howard. He added that the new facility is just another example of how they provide quality care to the community.

Harbin Clinic Calhoun is also home to the only cardiologist in the city. Dr. Vincent Pearson provides full cardiac care for Calhoun and surrounding areas, using state-of-the-art tests like cardiac CT and MRI scans to help accurately diagnose patients.

He also works closely with cardiovascular surgeons and provides follow-up office care for cardiac patients.

The specialty suite has three exam rooms, while the family medicine wing spans nearly 5,000 square feet with 12 exam rooms.

Harbin Clinic Calhoun recently added Nephrology to its growing list of specialty care.  Nephrology is the treatment and diagnosis of conditions affecting the kidneys. Dr. Rashid Ishaque is a highly trained nephrologist who cares for all aspects of renal disease, including acute renal failure in adults, inherited and acquired kidney problems, hypertension, management of body fluid and electrolyte disorder.

The clinic is open Monday through Friday from 8 a.m. to 5 p.m.

To make an appointment with Family Medicine and Cardiology, call 706-879-6600.  For Nephrology, call 770-276-7201.

...

 
IRIS Establishes Napa Meeting to Advance Leading-Edge Directions in Nephrology - PR Newswire (press release)
image IRIS

DAVIS, Calif., July 30, 2015 /PRNewswire/ -- The International Renal Interest Society (IRIS), a veterinary society established to advance the scientific understanding of kidney disease in small animals, announced today the creation of the IRIS Napa Meeting. This reoccurring meeting is a new strategic planning initiative to be held in the Napa Valley, California, as emerging critical issues in veterinary nephrology arise. This groundbreaking think-tank style summit will host globally renowned authorities in nephrology and provide problem recognition and innovative solutions to topical and complex issues affecting kidney health in dogs and cats. The inaugural meeting, held in May 2015, focused on recognition of early (subclinical) kidney disease and its role in progressive kidney injury.  Financial and logistical support for the inaugural Napa Meeting was graciously provided by IDEXX, Westbrook, Maine.

"Formation of the IRIS Napa Meeting provides an important leadership role for IRIS and groundbreaking opportunities for the nephrology community," said Dr. Larry Cowgill, IRIS Napa Meeting co-chair. 

The evolving opportunities of novel renal biomarkers that permit earlier recognition of chronic kidney disease (CKD) and acute kidney injury (AKI) as well as their potentially interrelated pathogenesis were the hallmark of the May meeting. Based on preliminary evidence with a spectrum of novel kidney biomarkers, an hypothesis emerged that progression of CKD may, in part, be perpetuated by "active" and ongoing kidney injury that remains undetected until structural losses of nephron mass is reflected in traditional "static" diagnostic markers of kidney function. If validated with future studies, this hypothesis could have a defining influence on the future diagnosis and management of early kidney disease.

"Napa Meetings are intended to facilitate focused discussions that will lead to solutions to fundamental issues in veterinary nephrology in a timely manner, thereby enabling veterinarians to stay at the forefront of new medical breakthroughs," said Dr. David Polzin, IRIS Napa Meeting co-chair.  

The complementary role of symmetric dimethylarginine (SDMA), a forthcoming kidney biomarker for the early detection of CKD, to conventional diagnostics for kidney disease and its role in the IRIS CKD Staging scheme were among the impactful issues discussed. Subsequent to recommendations from the Napa Panel and following further consideration at the 2015 IRIS Board Meeting, the following interpretive comments for the diagnostic and therapeutic utilization of SDMA were incorporated into the 2015 IRIS CKD Staging Guidelines and are expected to be available as soon as possible on the reconstructed IRIS website, www.iris-kidney.com.

"Serum or plasma SDMA may be a more sensitive biomarker of renal function compared with creatinine. A persistent elevation in SDMA above 14 µg/dl would indicate reduced renal function and be a reason to categorize a dog or cat (with creatinine values <1.4 or <1.6 mg/dl, respectively) as IRIS CKD Stage 1."

"In IRIS CKD Stage 2 patients with low body condition scores, if SDMA is ?25 µg/dl, this may indicate the extent of renal dysfunction has been underestimated. Consider treatment recommendations listed under IRIS CKD Stage 3 for this patient."

"In IRIS CKD Stage 3 patients with low body condition scores, if SDMA is ?45 µg/dl, this may indicate the degree of renal dysfunction has been underestimated. Consider treatment recommendations listed under IRIS CKD Stage 4 for this patient."

These additions to the guidelines are preliminary, based on early data derived from the use of SDMA in veterinary patients.  The IRIS Board fully expects them to be updated as the veterinary profession gains further experience using SDMA alongside the long-established marker, creatinine, in the diagnosis and therapeutic monitoring of canine and feline CKD.

Organizations or commercial entities with an interest in veterinary nephrology are invited to consider supporting future IRIS Napa Meetings with the goal of exploring new horizons and strategies in nephrology creatively designed for the next 10 years and beyond.  For more information about IRIS, visit www.iris-kidney.com. Those interested in sponsoring a future IRIS Napa meeting should contact Dr. Larry Cowgill at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or Dr. David Polzin at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

ABOUT IRIS

IRIS is the International Renal Interest Society and was organized originally at the 8th Annual Congress of the European Society of Veterinary Internal Medicine in Vienna, Austria, in 1998, with the support of Novartis Animal Health, which provided operational funding and organizational assistance until December 2014.  Current support for the educational and scientific missions of IRIS is provided by Elanco Animal Health, Greenfield, IN.

IRIS is composed of a board of 15 independent veterinarians with particular expertise in veterinary nephrology, from 10 different countries. The mission of IRIS is to help veterinary practitioners better diagnose, understand, and treat kidney disease in cats and dogs. In order to achieve this mission, the group investigates ways to more accurately diagnose early signs of acute and chronic kidney disease and provides consensus recommendations and explores novel therapies for their management.

One of the organization's primary objectives is to establish internationally recognized guidelines on the diagnosis and treatment of kidney diseases in dogs and cats.  IRIS has been a recognized leader for a variety of topics in the area of nephrology and a source of direction veterinarians look to for the diagnosis and management of kidney disease in animal patients.  IRIS is proud to add the Napa Meeting to its portfolio of accomplishments for the advancement of the science and understanding of kidney disease in animals.

CONTACTS:

Dr. Astrid van Dongen
President, IRIS
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Dr. Larry Cowgill
Co-Chair 2015 IRIS Napa Meeting
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Dr. David Polzin
Co-Chair 2015 IRIS Napa Meeting
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Logo - http://photos.prnewswire.com/prnh/20150729/249436LOGO

SOURCE IRIS

RELATED LINKS
http://www.iris-kidney.com

...

 
Eisai's Lenvima gets FDA breakthrough status for renal cell carcinoma - Pharmaceutical Business Review

Pharmaceutical Business Review

Eisai's Lenvima gets FDA breakthrough status for renal cell carcinoma
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Eisai's in-house developed new anticancer agent Lenvima (lenvatinib mesylate, lenvatinib) for the potential indication of advanced and/or metastatic renal cell ...
Eisai's Lenvima receives Breakthrough Therapy designation for renal cell carcinoma European Pharmaceutical Review
FDA grants breakthrough drug designation to Lenvima for advanced RCC Healio
Eisai's Lenvima breakthrough therapy for new indication PharmaTimes

all 8 news articles »

...

 
Australia's first bush dialysis service, Purple House, given $15.3m to expand - The Guardian

The federal government has announced $15.3m in funding for the central Australian dialysis service, the Purple House, to expand treatment to remote Indigenous communities experiencing a crisis in renal health.

The money includes $9m indexed over three years for renal service delivery, and $6.3 immediately for infrastructure – providing renal dialysis units in a number of remote communities.

Related: Charlie's story: life and death of the man forced to sleep rough while on dialysis

The Purple House is a largely self-funded dialysis clinic in Alice Springs for Indigenous patients from remote communities. It also provides dialysis services in some remote communities. It began 15 years ago with independent money raised by Aboriginal people, and was the first bush dialysis service in the country.

Indigenous people are more than four times more likely than non-Indigenous people to have stage-four or stage-five – advanced – kidney disease, and almost four times as likely to die from chronic kidney disease. End-stage kidney disease is 18 to 20 times higher for Indigenous people in remote and very remote areas.

Before Thursday’s announcement the organisation received $1.7m from the Northern Territory government, but it was not indexed.

“There is absolutely no doubt that Purple House and [its chief executive] Sarah Brown do a fantastic job in the delivery of these services,” said the assistant federal health minister, Fiona Nash. “It’s an absolute credit to them – the difference they make in people’s lives out in remote communities.”

Brown said the Purple House team was “gobsmacked” and said the money would “keep the doors open” for the next three years and recognised the clinic’s expansion.

“But it also means that communities where people have never got home on dialysis – they’ve come to town and they’re stuck there until they die – are going to have some hope for the future,” she said.

The news comes after Wednesday’s announcement of a plan to spend $10m in federal funds on dialysis support services for remote-living Indigenous patients in the Northern Territory, albeit four years after the money was offered.

Related: $10m for remote healthcare unveiled in NT, four years after federal offer

“Between the two announcements it’s not being overly dramatic to say that this changes the face of renal disease in Australia. No longer will dialysis mean a one-way ticket to town and home for your own funeral,” said Brown.

“People will have hope, they will have a reason to stay well, to get home, and families will be able to look after people. This is enormous for the whole of central Australia and for the people whose kidneys are failing now and who are trying to decide what they’re going to do. So thank you.

“There are going to be a few parties in Alice Springs hostels tonight as people party and plan their trips home.”

The new money would create about 16 dialysis chairs out bush in places where there is little or no service, and allow Purple House to act on plans it has had for years to expand into the east of the NT and into parts of South Australia.

Greens senator Rachel Siewert, whose has repeatedly pushed the issue of the $10m funding in Senate estimates, said it was “fantastic after all these years to finally see it being committed”.

“If the community hadn’t been hassling and if we hadn’t been hassling that money would have disappeared – it nearly disappeared into consolidated revenue a couple of times,” Siewert told Guardian Australia.

“It’s really good and the extra money for Purple House is fantastic … The projects are good that it’s going to so hopefully it will make a difference.”

The government has to invest in preventive health as well as treatment: “We also need to make sure we’re investing in the preventative side so we start dropping the numbers of people who will need this kind of support.”

Nash, who was in Darwin for a conference on improving Indigenous health, said the two announcements were not just about treatment but also about prevention, pointing to $1.4bn in primary healthcare funding committed to by the government.

The Purple House is a world’s best practice model of health care

Jennifer Westacott

“It’s double-handed,” she said. “We’ve got to, of course, make sure we have funding available for things like the renal service delivery and infrastructure we’ve seen in the last two days.

“But it’s also vitally important we focus on that primary prevention and making sure those services at the front line looking after these patients dealing with chronic disease are able to do so.”

Jennifer Westacott, chief executive of the Business Council of Australia, which partners with Purple House, praised the increased funding.

“In a time of fiscal restraint for governments, this decision recognises that the right kind of investment ticks every box,” Westacott said.

“The Purple House is a world’s best practice model of health care, the kind we need to see more of in Australia.”

Warren Snowdon, Labor’s parliamentary secretary for Indigenous affairs, who was federal minister at the time the initial $10m funding offer was made, also welcomed the funds.

Australia's first bush dialysis service, Purple House, given $15.3m to expand - The Guardian Greens senator Rachel Siewert: ‘It’s fantastic after all these years to finally see it being committed.’ Photograph: Mick Tsikas/AAP

“It has been disappointing that up until now both Labor and CLP NT governments wouldn’t take responsibility for expanding the delivery of dialysis and renal services, while the commonwealth was prepared to contributing infrastructure funding,” he said.

“It is now pleasing that the commonwealth and territory are working together for central Australian Indigenous renal patients and their families.”

Also on Thursday, Nash, the NT health minister, John Elferink, and Marion Scrymgour, the chair of the Aboriginal services alliance of NT (Amsant), announced a recommitment to a framework agreement aimed at improving the health and wellbeing of Indigenous people.

The renewed five-year agreement “promotes shared responsibility and the need for genuine ongoing partnerships between Aboriginal community-controlled health services and both levels of government,” said Nash.

It commits all parties to share information and identify “key priorities for action” and was an “in principles agreement”, not about specifics, Nash said.

Elferink said the agreement would also focus on health data collection, which already had demonstrated success in the NT.

The agreement was the start of a national approach with the expectation other states and territories would sign similar agreements this year.

...

 
Dialysis services in Northern Territory get $25m Federal funding boost - ABC Online

ABC Online

Dialysis services in Northern Territory get $25m Federal funding boost
ABC Online
The Federal Government has unlocked more than $25 million for dialysis services which will predominantly target Indigenous people living with chronic kidney disease. Today at the Aboriginal Health Conference in Darwin, federal Assistant Health Minister ...
Australia's first bush dialysis service, Purple House, given $15.3m to expand The Guardian
NT renal patients to get $15.3m help 9news.com.au

all 9 news articles »

...

 
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Page 31 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.